With all due respect, please be aware that some of this is surmising since I am not an intellectual property expert, but the issue seems to be around timing, and particularly around the timing of the production of these vaccines.
I mentioned earlier that the director general of the WTO had a third way proposal, where she talked to industries about the issues they were facing with respect to vaccine production. None of them mentioned intellectual property as the problem. They talked about other issues, like inputs, for example, and actually having the technical expertise, and the people who could deliver on the manufacturing, particularly on the mRNA, which is quite complex. Supply chain predictability was another issue.
Some of the countries that are holding the IP, I would imagine, are thinking that they should probably be spending more time addressing those issues that have been identified as the real stumbling blocks to vaccine production.
There's a range of issues not related to the IP itself.